Koyfin Home > Directory > Health Care > Adma Biologics > EBIT

Adma Biologics EBIT Chart (ADMA)

Adma Biologics annual/quarterly EBIT from 2010 to 2020. Earnings before interest and taxes measures the profit a company generates from its operations, making it synonymous with operating profit. By ignoring tax and interest expenses, it focuses solely on a company's ability to generate earnings from operations, ignoring variables such as the tax burden and capital structure.
  • Adma Biologics EBIT for the quarter ending June 06, 2020 was $-17m a 47.15% decrease of -8m year over year
  • Adma Biologics EBIT for the last 12 months ending June 06, 2020 was $-51m a 1.23% decrease of -1m year over year
  • Adma Biologics Annual EBIT for 2019 was $-41m a -45.54% increase of 19m from 2018
  • Adma Biologics Annual EBIT for 2018 was $-60m a 32.05% decrease of -19m from 2017
  • Adma Biologics Annual EBIT for 2017 was $-41m a 57.69% decrease of -24m from 2016
Other Income Statement Metrics:
  • Adma Biologics EBITDA for the quarter ending December 12, 2018 was $-16m a -0.51% increase of 0m year over year
  • Adma Biologics Net Income for the quarter ending December 12, 2018 was $-18m a 1.20% decrease of 0m year over year
  • Adma Biologics Total Revenue for the quarter ending September 09, 2018 was $4m a -183.74% decrease of -8m year over year
View Chart On Koyfin

Quarterly ADMA EBIT Data

06/2020$-17m
03/2020$-17m
12/2019$-8m
09/2019$-9m
06/2019$-11m
03/2019$-13m
12/2018$-17m
09/2018$-14m
06/2018$-13m
03/2018$-17m

Annual ADMA EBIT Data

2019$-41m
2018$-60m
2017$-41m
2016$-17m
2015$-16m
2014$-16m
2013$-15m
2012$-8m
2011$-3m
2010$-5m